Hepatitis
Featured Article
The FDA has issued a drug safety warning about the use of 3 medications for hepatitis C virus among individuals with moderate to severe liver impairment.
Researchers recently compared how the use of lipophilic or hydrophilic statins impacted hepatocellular carcinoma in patients with viral hepatitis.
A recent study investigated whether drug manufacturers saw increased net revenue after reduced list prices for hepatitis C treatments and changes to discounts provided under the 340B program.